Trial Information

Official Title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease

Summary

The purpose of the study is to evaluate safety and the pharmacodynamic effects of BMS-241027 on cerebrospinal fluid (CSF) Tau, connectivity magnetic resonance imaging (MRI), and computerized cognitive tests in mild Alzheimer's disease (AD) subjects, following 9 weekly intravenous (IV) infusions of BMS-241027

Phase: Phase 1

Sponsor: Bristol-Myers Squibb

Overall Contacts:

For participation information at a USA site use a phone number below. For site information outside the USA please email:

Clinical.Trials@bms.com

First line of email MUST contain NCT# & Site#. Only trial sites that are recruiting have contact information at this time.